346
Views
5
CrossRef citations to date
0
Altmetric
Drug Profile

Efficacy and safety of high-dose ciclesonide for the treatment of severe asthma

Pages 339-348 | Published online: 09 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Søren E Pedersen, Niyati Prasad, Udo-Michael Goehring, Henrik Andersson & Dirkje S Postma. (2017) Control of moderate-to-severe asthma with randomized ciclesonide doses of 160, 320 and 640 μg/day. Journal of Asthma and Allergy 10, pages 35-46.
Read now

Articles from other publishers (4)

Demétrius Tierno Martins, Karla Carlos, Luciane Bizari Carvalho, Lucila Bizari Prado, Carolina Fransolin, Alvaro Nagib Atallah & Gilmar Fernandes do Prado. (2022) A randomized clinical trial on inhaled ciclesonide for managing acute asthma in the emergency room. Sao Paulo Medical Journal 140:3, pages 430-438.
Crossref
Yuzhu Xu, Hongxu Wu, Xiaojie Wu, Yongjian Xu, Jianping Zhao, Jungang Xie & Jun Yu. (2017) GLCCI1 rs37973. Medicine 96:52, pages e9442.
Crossref
Anna Bodzenta-Łukaszyk & Marek Kokot. (2014) Pharmacological Consequences of Inhaled Drug Delivery to Small Airways in the Treatment of Asthma. Advances in Therapy 31:8, pages 803-816.
Crossref
Rafał Pawliczak. (2014) Leczenie przeciwzapalne w astmie. Alergologia Polska - Polish Journal of Allergology 1:1, pages 38-42.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.